Recent advances in hyperthermia therapy‐based synergistic immunotherapy
The past decades have witnessed hyperthermia therapy (HTT) as an emerging strategy
against malignant tumors. Nanomaterial‐based photothermal therapy (PTT) and magnetic …
against malignant tumors. Nanomaterial‐based photothermal therapy (PTT) and magnetic …
Thyroid dysfunction and diabetes mellitus: two closely associated disorders
B Biondi, GJ Kahaly, RP Robertson - Endocrine reviews, 2019 - academic.oup.com
Thyroid dysfunction and diabetes mellitus are closely linked. Several studies have
documented the increased prevalence of thyroid disorders in patients with diabetes mellitus …
documented the increased prevalence of thyroid disorders in patients with diabetes mellitus …
Nanoparticle‐enhanced radiotherapy to trigger robust cancer immunotherapy
External radiotherapy is extensively used in clinic to destruct tumors by locally applied
ionizing‐radiation beams. However, the efficacy of radiotherapy is usually limited by tumor …
ionizing‐radiation beams. However, the efficacy of radiotherapy is usually limited by tumor …
Endocrine toxicity of cancer immunotherapy targeting immune checkpoints
Immune checkpoints are small molecules expressed by immune cells that play critical roles
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
MZ Wojtukiewicz, MM Rek, K Karpowicz… - Cancer and Metastasis …, 2021 - Springer
The treatment of cancer patients with immune checkpoint inhibitors (ICI)(anti-CTLA-4, anti-
PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) has without doubt …
PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) has without doubt …
Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
A therapeutic strategy that can eliminate primary tumours, inhibit metastases, and prevent
tumour relapses is developed herein by combining adjuvant nanoparticle-based …
tumour relapses is developed herein by combining adjuvant nanoparticle-based …
Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions
M Ralli, A Botticelli, IC Visconti… - Journal of …, 2020 - Wiley Online Library
Melanoma is one of the most immunologic malignancies based on its higher prevalence in
immune‐compromised patients, the evidence of brisk lymphocytic infiltrates in both primary …
immune‐compromised patients, the evidence of brisk lymphocytic infiltrates in both primary …
Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
C Hinterleitner, J Strähle, E Malenke… - Nature …, 2021 - nature.com
Immune-checkpoint inhibitors (ICI) have transformed oncological therapy. Up to 20% of all
non-small cell lung cancers (NSCLCs) show durable responses upon treatment with ICI …
non-small cell lung cancers (NSCLCs) show durable responses upon treatment with ICI …
Autoimmune polyendocrine syndromes
ES Husebye - The Rose and Mackay Textbook of Autoimmune …, 2024 - Elsevier
Autoimmune polyendocrinopathies are traditionally divided into two distinct syndromes,
autoimmune polyendocrine syndrome type 1 and 2 (APS-1 and-2). The first is a monogenic …
autoimmune polyendocrine syndrome type 1 and 2 (APS-1 and-2). The first is a monogenic …
[HTML][HTML] Immune-related adverse events with immune checkpoint blockade: a comprehensive review
JM Michot, C Bigenwald, S Champiat, M Collins… - European journal of …, 2016 - Elsevier
Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in
which therapeutic agents are used to target immune cells rather than cancer cells. The first …
which therapeutic agents are used to target immune cells rather than cancer cells. The first …